
|Articles|October 1, 2002
Angiogenesis research provides foundation for drug development
Paris - Increased understanding of the basic molecular mechanisms involved in angiogenesis has suggested new targets for treating a number of dermatological and other diseases, and many compounds affecting angiogenesis are in clinical trials. However, questions remain to be answered about potential strategies for optimizing the efficacy of pro- and anti-angiogenic interventions and the safety of these novel treatments, Peter Carmeliet, Ph.D., said at the World Congress of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
JAK Inhibitors Show Comparable Safety to TNF Antagonists
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















